25-09-02	PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE for Patients with Wagner 1 Diabetic Foot Ulcers	CI
25-08-26	PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers	CI
24-05-19	RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC	CI
24-02-26	PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers	CI
23-08-18	PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer	CI
23-08-18	PolarityTE, Inc. Announces Executive Changes	CI
23-08-18	PolarityTE, Inc. has Changed its Name to RegenETP, Inc	CI
23-08-14	Grander Acquisition LLC completed the acquisition of Substantially all of the assets of PolarityTE, Inc..	CI
23-08-01	PolarityTE, Inc. Announces the Resignation of Jeff Dyer from the Company's Board of Directors	CI
23-06-15	PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index	CI
23-06-13	PolarityTE, Inc.(NasdaqCM:PTE) dropped from S&P TMI Index	CI
23-06-06	Grander Acquisition LLC entered into a stalking horse asset purchase agreement to acquire Substantially all of the assets of PolarityTE, Inc. for $6.5 million.	CI
23-05-15	North American Morning Briefing : Hopes Build for -3-	DJ

Analysts' recommendations: RegenETP, Inc.

22-12-28	Northland Securities Adjusts Price Target on PolarityTE to $1 From $1.25, Maintains Outperform Rating	MT
22-03-31	Cantor Fitzgerald Downgrades PolarityTE to Neutral From Overweight, Adjusts Price Target to $1 From $2.50	MT

23-08-15	PolarityTE : Acquisition/Asset Disposal - Form 8-K	PU
23-06-07	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-06-07	POLARITYTE, INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23-04-26	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-03-27	POLARITYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ

1 day

-8.24%

Manager	Title	Age	Since
Richard Hague CEO	Chief Executive Officer	65	2021-08-31
Ryan Mathis CTO	Chief Tech/Sci/R&D Officer	-	2021-08-31
Nikolai Sopko CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Richard Hague BRD	Director/Board Member	65	2023-08-17

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
REGENETP, INC.	-8.24%	+0.65%	-	-	1.12M
CHURCHILL CAPITAL CORP VII	-0.30%	-.--%	-.--%	-0.70%	915M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.20%	-0.10%	-	-	652M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	-.--%	-.--%	-.--%	600M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.20%	-0.39%	-	-	592M
CANTOR EQUITY PARTNERS IV, INC.	+0.29%	-0.29%	-	-	591M
CHURCHILL CAPITAL CORP XI	0.00%	-0.10%	-	-	566M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-1.33%	+0.91%	-	-	556M
NEW AMERICA ACQUISITION I CORP.	0.00%	+0.10%	-	-	502M
CAPITOL INVESTMENT CORP. VII	-.--%	-.--%	-	-	500M
Average	-0.96%	+0.03%	-.--%	-0.35%	608.22M
Weighted average by Cap.	-0.15%	+0.02%	-.--%	-0.42%